marketing assignment on" NOVARTIS"

1. Presentation On NOVARTIS (A PHARMACEUTICAL COMPANY) SHIVANI KAKRIA

4. SLOGAN OF NOVARTIS CARING AND CURING

5. MISSION INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.

7. HUMAN RESOURCE BUILDING OF NOVARTIS IN BASEL.

8. KEY PEOPLE CHAIRMAN : DANIEL VASELLA CEO: JOSEPH JIMENEZ

10. NETINCOME:US$8.40BILLION

11. OPERATING INCOME:US $9.98

12. EMPLOYEES:99,830

15. SHARE ANALYSIS OF NOVARTIS

16. GROWTH IN VARIOUS PRODUCT CATEGORIES…..

18. RUSSIA

19. TURKEY

20. SOUTH KOREA

21. BRAZIL

23. EMERGING MARKKETS IN PHARMACEUTICALS..

26. FOUNDED IN 1996,

27. HD.QT’S-BASEL AND SWITZERLAND.

29. IS MEMBER OF EUROPEAN FEDERATION OFPHARMACEUTICAL INDUSTRIES ANDASSOCIATION.

30. NOVERTIS PRODUCTS

31. USD FIXED INCOME SECURITIES

32. FINANCIAL DEVELOPMENTS IN 2009 NET SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION. PHARMACEUTICALS: RANKS AS ONE OF THE INDUSTRY FAST GROWING COMPANIES IN 2009 WITH NET SALES OF 8%(+12% IN LC) TO USD 28.5BILLION. VACCINES AND DIAGNOSTICS:38%(39% IN LC) NET SALES INCCREASE TO USD 2.4 BILLION.. SANDOZ: NET SALES FALLS 1% TO USD 7.5 BILLION BUT RISE 5%LC AS NEGATIVE CURRENCY OVERSHADOWS OPERATIONAL GAINS FROM NEW LAUNCHES. CONSUMER HEALTH:EXPAND MARKET SHARE IN ALL BUSINESS ECONOMIC ACTIVITIES WITH SALES OF USD 5.8 BILLION. ;

33. SOME OTHER FINANCIAL DEVELOPMENTS OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANSIONAND PRODUCTIVITY GAINS MORE DUE TO NEGATIVE IMPACT OF LOCAL CURRENCY. NET INCOME:GROWS 4% TO USD 8.5 BILLION DUE TO RELATED FINANCIAL COST AND INCOME FROM ASSOCIATED COMPANIES. BASIC EARNING PER SHARE:RISE FROM 3% TO 3.70,CORE EPS RISES FROM 8% TO USD 4.50. DIVIDEND:INCREASES 3.7% PRODUCTIVITY:EXCEEDING THE TARGET BY 0.7 BILLION.

35. VACCINES AND DIAGNOSTICS

36. SANDOZ(GENERICS)

37. OVER THE COUNTER

38. ANIMAL HEALTH

40. HEALTHCARE OTC Benefiber Buckley's cold and cough formula Bufferin Comtrex cold and cough Denavir/Vectavir Desenex Doan's pain relief Ex-Lax Excedrin Fenistil Gas-X Habitrol Keri skin care Lamisil foot care Lipactin Herpes symptomatic treatment Maalox Nicotinell No-doz

42. NET SALES BY REGION IN %

43. CORE OPERATING INCOME BY DIVISION IN %

44. NET SALES BY DIVISION IN %

45. COMPETITORS IN INDIA NAME OF THE COUNTRY DR.REDDY’S LAB CIPLA PIRAMAL HEALTHCARE GLAXO INDIA LTD. SUN PHARMACEUTICAL TOTAL REVENUE (IN USD BILLIONS) 1.5 1.28 0.84 0.43 0.42

46. COMPETITORS IN SWITZERLAND TOTAL REVENUE (IN USD BILLIONS) 47.35 4.26 NAME OF THE COUNTRY HOFFMAN LA ROCHE 2.NYCOMED

47. COMPETITORS IN GERMANY NAME OF THE COUNTRY BAYER BOEHRINGER INGELHEIM MERCK kGaA TOTAL REVENUE (IN USD BILLIONS) 22.3 16.9 5.17

48. COMPETITORS IN JAPAN NAME OF THE COUNTRY TAKEDAPHARMACEUTICAL. ASTELLAS PHARMA DAIICHI SANKYO 9 EISAI CHUGAI PHARMACEUTICAL . TOTAL REVENUE (IN USD BILLIONS) 15.6 10.7 9 5.5 2.0

49. COMPETITORS IN USA TOTAL REVENUE(IN USD BILLIONS ) 61.90 30.76 27.43 21.84 18.81 NAME OF THE COMPANY JOHNSON AND JOHNSON ABOTT LABORATORIES MERC K AND CO. ELI LILLY BRISTOL MAYER SQUIBB

50. COMPETITORS IN UK NAMEOF THE COMPANY TOTAL REVENUE (IN USD BILLIONS) 45.83 32.81 GlaxoSmithKline AstraZeneca

54. 2009 net sales - USD 7.5 billion DIOVAN

56. MOL.MAS:435.519G/MOL

58. Protein binding:95%

59. Half life :6hours

61. HEART FAILURE AND

66. IN PAKISTAN ,IT IS MARKETED UNDER TRADE MARK ANGIOTAN.

70. SIDE EFFECTS OF DIOVAN LEADS TO HEADACHE AND DIZZINESS. SENSTIVITY TO SUNLIGHT AND BRIGHT ARTIFICIAL LIGHT. THERE IS A CASE OF A STILLBIRTH IN WHICH VALSARTAN IS IMPLICATED.

71. THANKS